Prot #XB99016/NU 19L01: Phase Ib Study of Brigatinib Plus Bevacizumab in Patients with ALK-rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy

  • Villaflor, Victoria Meucci (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/16/19 → 9/16/22

Funding

  • Millennium Pharmaceuticals, Inc (Prot #XB99016/NU 19L01)